Mei Xi, Zhao Zheng, Wang Juan, Qiu Conglong, Li Longhui, Xiong Changchun, Zhu Shanshan, Zheng Chengying
Department of Psychiatry, Affiliated Kangning Hospital of Ningbo University, Ningbo, Zhejiang, China.
Department of Psychiatry, Ningbo Kangning Hospital, Ningbo, Zhejiang, China.
Front Neurol. 2025 Jul 2;16:1615457. doi: 10.3389/fneur.2025.1615457. eCollection 2025.
Objective tests that can be used to identify neurodegenerative diseases and neuropsychiatric disorders are urgently needed. The primary objective of this study is to evaluate the diagnostic accuracy of surface-enhanced Raman spectroscopy (SERS), a novel blood-based detection method, in differentiating neurodegenerative diseases and neuropsychiatric disorders. Additionally, we aim to assess the synergistic diagnostic performance of combining SERS with enzyme-linked immunosorbent assay (ELISA) technology for Alzheimer's disease (AD), mild cognitive impairment (MCI), and late-life depression (LLD).
In total, 23 patients with AD, 24 with MCI, 20 with LLD, and 20 cognitively normal (control) individuals were enrolled. ELISA and SERS were used to test various biomarkers in the AD, MCI, LLD, and control groups.
Amyloid-β, tau, brain-derived neurotrophic factor, proinflammatory cytokine IL-1β, and growth differentiation factor-15 levels as measured using ELISA significantly differed among the four groups ( < 0.05). SERS peaks at 592 ( = 0.038), 725 ( = 0.001), 1,003 ( = 0.010), 1,331 ( = 0.000), and 165 cm ( = 0.000) likewise significantly differed among the four groups. The area under the curve was significantly higher after combining multiple blood indicators than that with single-blood indicators.
Combining SERS and ELISA can significantly increase diagnostic accuracy for AD, MCI, and LLD. The findings are expected to provide potential therapeutic targets for precise intervention in these diseases, thereby contributing to improved clinical stratification and personalized treatment strategies.
ChiCTR2300076307 (30/09/2023).
迫切需要能够用于识别神经退行性疾病和神经精神障碍的客观测试。本研究的主要目的是评估表面增强拉曼光谱（SERS）这一新型血液检测方法在区分神经退行性疾病和神经精神障碍方面的诊断准确性。此外，我们旨在评估将SERS与酶联免疫吸附测定（ELISA）技术相结合用于阿尔茨海默病（AD）、轻度认知障碍（MCI）和老年期抑郁症（LLD）的协同诊断性能。
共纳入23例AD患者、24例MCI患者、20例LLD患者和20名认知正常（对照）个体。使用ELISA和SERS检测AD、MCI、LLD和对照组中的各种生物标志物。
使用ELISA测量的淀粉样β蛋白、tau蛋白、脑源性神经营养因子、促炎细胞因子IL-1β和生长分化因子-15水平在四组之间存在显著差异（<0.05）。SERS在592（=0.038）、725（=0.001）、1003（=0.010）、1331（=0.000）和165 cm（=0.000）处的峰在四组之间同样存在显著差异。联合多种血液指标后的曲线下面积显著高于单一血液指标。
将SERS和ELISA相结合可显著提高AD、MCI和LLD的诊断准确性。这些发现有望为这些疾病的精准干预提供潜在治疗靶点，从而有助于改善临床分层和个性化治疗策略。
ChiCTR2300076307（2023年9月30日）。
